Altendorf T, Gering I, Santiago-Schübel B, Aghabashlou Saisan S, Tamgüney G, Tusche M, Honold D, Schemmert S, Hoyer W, Mohrlüder J, Willbold D Stabilization of monomeric Tau protein by all D-enantiomeric peptide ligands as therapeutic strategy for Alzheimer's disease and other tauopathies Int J Mol Sci 24, 2161 (2023) https://doi.org/10.3390/ijms24032161
König AS, Rösener NS, Gremer L, Tusche M, Flender D, Reinartz E, Hoyer W, Neudecker P, Willbold D, Heise H Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy J Biol Chem 296, 100499 (2021) https://doi.org/10.1016/j.jbc.2021.100499
Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid Eur J Pharm Sci. , (2020) https://pubmed.ncbi.nlm.nih.gov/33035662/
Elfgen A, Hupert M, Bochinsky K, Tusche M, González de San Román Martin E, Gering I, Sacchi S, Pollegioni L, Huesgen PF, Hartmann R, Santiago-Schübel B, Kutzsche J, Willbold D. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers Sci Rep 9(1), 5715 (2019) http://10.1038/s41598-019-41993-6 https://www.nature.com/articles/s41598-019-41993-6
Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. J Alzheimers Dis 64(3), 859-873 (2018) https://10.3233/JAD-180165 https://www.ncbi.nlm.nih.gov/pubmed/29966196
Boeske A, Schwarten M, Ma P, Tusche M, Mötter J, Möller C, Neudecker P, Hoffmann S, Willbold D Direct binding to GABARAP family members is essential for HIV-1 Nef plasma membrane localization Scientific Reports 7, 5979 (2017)
Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D Optimization of D-peptides for Aβ monomer binding specificity enhances their potential to eliminate toxic Aβ oligomers ACS Chem Neurosci 8, 1889-1900 (2017)
Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. Molecules 22(10), (2017) http://10.3390/molecules22101693 https://www.ncbi.nlm.nih.gov/pubmed/28994710
Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. Eur J Pharm Sci. 17, 0928-0987 (2017) https://doi.org/10.1016/j.ejps.2017.12.005 https://www.ncbi.nlm.nih.gov/pubmed/29225107
van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep. 7, 16275 (2017) https://doi.org/10.1038/s41598-017-16565-1 https://www.nature.com/articles/s41598-017-16565-1
Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D. Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. PLoS One 11(4), (2016) http://dx.doi.org/10.1371/journal.pone.0153035 Erratum in: PLoS One. 2016;11(7):e0158960. http://dx.doi.org/10.1371/journal.pone.0158960
Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, Kutzsche J, Reiß K, Gremer L, Nagel-Steger L, Willbold D. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. ACS Chem Neurosci. 7 (8), 1088–1096 (2016) http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00047
Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. Sci Rep 5, 13222 (2015) http://dx.doi.org/10.1038/srep13222
